supported by the National Science and Technology Major Project for Major New Drug Innovation (Nos.2013ZX09102064 and 2014ZX09201042-003)
In this study,N-terminal site-specific mono-PEGylation of the recombinant lidamycin apoprotein(r LDP) of lidamycin(LDM) was prepared using a polyethyleneglycol(PEG) derivative(Mw20 k Da) through a reactive terminal al...
supported by the Significant New Drugs Development Science and Technology Major Projects of China(2010ZX09401-407);State-level Public Welfare Scientific Research Institutes for Basic R&D Special Fund(IMBF201101)
The main goal of this study was to investigate whether lidamycin (LDM) could enhance the efficacy of paclitaxel (TAX) against breast cancer. In the MTT assay, LDM showed much more potent cytotoxicity than paclitaxel, ...
supported by grants from the National Natural Science Foundation of China (No. 30672482);the National 973 Program (No. 2009CB521807)
Objective Lidamycin, an enediyne antibiotic, leads to apoptosis and mitotic cell death of human tumor cells at high and low concentrations. The reason why tumor cells have distinct responses to lidamycin remains elusi...
This work was supported by The National High Technology Research and Development Program of China (No 2004AA2Z3950) and a grant from the National Natural Science Foundation of China (No 30400597).
Aim: To investigate the effects on human pancreatic cancer PANC- 1 and SW1990 cells using a combination of lidamycin (LDM) and gemcitabine. Methods: A 3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid...
Supported by the National High Technology Research and Development Program of China (863 Program)(Grant No. 2006AA02A255)
Type IV collagenase plays a pivotal role in invasion, metastasis and angiogenesis of tumor. Single domain antibodies are attractive as tumor-targeting vehicle because of their much smaller size com-pared with antibody...
Supported by the National High Technology Research and Development Program of China, 863 Program, No. 2002AA2Z346D
AIM: Type IV collagenase including MMP-2 and -9 plays an important role in cancer cell invasion and metastasis and is an attractive target for rnAb-directed therapy. The irnrnunoreactivity of rnAb 3G11, a rnAb direct...
Supported by the National High Technology Research and Development Program of China (863 program), No. 2002AA2Z3107
AIM: To study the in vitro and in vivo antitumor effect of lidamycin (LDM) on hepatoma and the active moiety of its molecule.METHODS: MTT assay was used to determine the growth inhibition of human hepatoma BEL-7402 ce...
Supported by the National High Technology Research and Development Program of China (863 Program), No. 2003AA2Z347D
AIM: To investigate the tissue distribution, urinary and fecal excretions of 125I-lidamycin (125I-C-1027) in mice and its biliary excretion in rats. METHODS:The total radioactivity assay (RA method) and the radioactiv...
Supported by Grants from the Major State Basic Research Development Program Foundation of China,No.G2000057010 and G 1999053901 and Grants from the National Natural Science Foundation of China,No.30271438 and 30300424 and Grant from the Key Laborator
AIM: Mitotic cell death has been focused on in tumor therapy.However, the precise mechanisms underlying it remain unclear. We have reported previously that enediyne antibiotic lidamycin induces mitotic cell death at l...
Project supported by the National Natural Science Foundation of China (№ 30070878) and Major State Basic Research Development Program Foundation of China (№ G2000057010).
To further study the effect of enediyne antibiotic lidamycin (C1027) on genomic DNA in human hepatoma BEL-7402 cells. METHODS: The DNA patterns were detected by agarose gel electrophoresis. The gene damage was reveale...